Search Results

You are looking at 1 - 10 of 33 items for :

  • somatostatin receptor ligand x
Clear All
Open access

Presurgical somatostatin receptor ligand treatment does not affect tumor consistency in GH-secreting pituitary macroadenomas

Marta Araujo-Castro, Héctor Pian, Ignacio Ruz-Caracuel, Alberto Acitores Cancela, Eider Pascual-Corrales, and Víctor Rodríguez Berrocal

, tumor consistency was reported to be an important predictive factor since hard consistency could impede transsphenoidal resection, especially in macroadenomas ( 8 ). Preoperative somatostatin receptor ligands (SRLs) treatment is proven to reduce GH and

Open access

Somatostatin receptor expression and clinical outcome of multilineage pituitary tumours expressing PIT1 and SF1

Prishila Fookeerah, Winny Varikatt, Meena Shingde, Mark A J Dexter, and Mark McLean

patient with mild biochemical persistence was treated with a somatostatin receptor ligand (SRL) resulting in normalisation of IGF-1. Of the two residual macrotumours, one was lost to follow-up and the other was managed with SRL with subsequent

Open access

Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours

Erik Rösner, Daniel Kaemmerer, Elisa Neubauer, Jörg Sänger, and Amelie Lupp

-8) for 16 min at 600 W and incubated with primary anti-PD-L1 antibody overnight at 4°C. To stain somatostatin receptors (SST) 1, 2, 3, 4, and 5, CXC motif chemokine receptor 4 (CXCR4), chromogranin A (CgA), and the proliferation marker Ki-67, the same

Open access

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR

Peter Wolf, Alexandre Dormoy, Luigi Maione, Sylvie Salenave, Jacques Young, Peter Kamenický, and Philippe Chanson

pegvisomant both improve insulin sensitivity ( 6 ), glucose metabolism may improve or worsen when patients are treated with first-generation somatostatin receptor ligands (SRLs), octreotide and lanreotide ( 7 , 8 , 9 , 10 ). Pasireotide is a somatostatin

Open access

Somatostatin receptor expression in parathyroid neoplasms

Sara Storvall, Helena Leijon, Eeva Ryhänen, Johanna Louhimo, Caj Haglund, Camilla Schalin-Jäntti, and Johanna Arola

scarce. Ligand binding to somatostatin receptors induces receptor internalization by endocytosis for the lysosomal regrading or recycling of the receptor to the plasma membrane ( 36 , 37 ). This could represent one mechanism explaining the cytoplasmic

Open access

Novel therapies for acromegaly

Bernardo Maia, Leandro Kasuki, and Mônica R Gadelha

patients have clinical contraindications or refuse to be submitted to surgery ( 4 , 10 ). Currently, there are three classes available for the treatment of acromegaly: somatostatin receptor ligands (SRLs), dopamine agonists, and GH receptor antagonist ( 4

Open access

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, and Albert Beckers

Ferone D . Somatostatin receptor ligands in the treatment of acromegaly . Pituitary 2017 20 100 – 108 . ( ) 10.1007/s11102-017-0791-0 28176162 17 Körner M Waser B Christ E Beck J Reubi JC . A critical

Open access

VPAC2 receptor expression in human normal and neoplastic tissues: evaluation of the novel MAB SP235

Stefan Schulz, Anika Mann, Benjamin Novakhov, Hugh D Piggins, and Amelie Lupp

Introduction The overexpression of receptors for small regulatory peptides, e.g. somatostatin, bombesin, vasoactive intestinal peptide (VIP) or pituitary adenylate cyclase-activating peptide (PACAP) provides the opportunity for effective clinical

Open access

Endocrinology and the brain: corticotropin-releasing hormone signaling

Carolina Inda, Natalia G Armando, Paula A dos Santos Claro, and Susana Silberstein

). Colored arrows show ligand-receptor interactions, with gray arrows indicating lower affinity. CRH binds to both receptors but with higher affinity to CRHR1. UCN1 is a high affinity ligand to both CRHR1 and CRHR2, whereas UCN2 and UCN3 are considered

Open access

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari, and S Cannavò

-018-0865-7 ) 29344905 10.1007/s11102-018-0865-7 21 Cuevas-Ramos D Fleseriu M . Somatostatin receptor ligands and resistance to treatment in pituitary adenomas . Journal of Molecular Endocrinology 2014 52 R223 – R240 . ( ) 10